Keyphrases
Inflammatory Rheumatic Diseases
100%
DANBIO Registry
97%
COVID-19 Pandemic
59%
Biosimilar
46%
Inflammatory Arthritis
44%
Patient Characteristics
42%
Patient-reported Outcomes
37%
Self-isolation
33%
Online Systems
26%
Real Patients
26%
Infliximab Biosimilar
23%
Rheumatoid Arthritis
22%
Routine Care
21%
Axial Spondyloarthritis (AxSpA)
18%
Psoriatic Arthritis
18%
Rheumatology
17%
Disease Activity
16%
Patient Satisfaction
15%
Retention Rate
13%
Nuclear Medicine
13%
Large-scale Implementation
13%
Strategy Behavior
13%
Sarcoidosis
13%
Vaccine Impact
13%
User Characteristics
13%
CoV-19
13%
Behavior Change
13%
Adalimumab
13%
Randomized Clinical Trial
13%
Treat-to-target
13%
Switcher
13%
Clinical Outcomes
13%
Nationwide Survey
13%
COVID-19 Pandemic Impact
13%
Treatment Outcome
13%
Frequent Testing
13%
Self-protection
13%
Etanercept
13%
SARS-CoV-19
13%
Nave
13%
Protection Strategy
13%
Comparative Effectiveness
13%
Nationwide Observational Study
13%
Health Behavior
13%
Clinical Factors
13%
GP2017
13%
Adalimumab Biosimilar
13%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
13%
Remission Rate
12%
Early Disease
10%
Medicine and Dentistry
Rheumatic Disease
80%
COVID-19
59%
Rheumatoid Arthritis
47%
Biosimilar
39%
Consultation
19%
Patient-Reported Outcome
18%
Disease Activity
17%
Spondylarthritis
16%
Psoriatic Arthritis
16%
Infection
15%
Observational Study
14%
Tattoo
13%
Etanercept
13%
Nuclear Medicine
13%
Sarcoidosis
13%
Adalimumab
13%
Health Behavior
13%
Infliximab
13%
SARS Coronavirus
13%
Behavioral Change
13%
Randomized Clinical Trial
13%
Spontaneous Remission
9%
Cohort Study
8%
Proportional Hazards Model
8%
Disease
8%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
COVID-19 Vaccination
7%
Fluorodeoxyglucose F 18
7%
Logistic Regression Analysis
7%
Social Distancing
6%
Online Monitoring
6%
Chronic Disease
6%
Health Care
6%
Disease-Modifying Antirheumatic Drug
5%
Attitude
5%
